Shipment of Afluria Vaccine Commences in Time for Flu Season

Krystle Vermes
Published Online: Tuesday, August 12, 2014
Follow Pharmacy_Times:
Pennsylvania-based vaccine producer, bioCSL, Inc, has started shipping its influenza vaccine, Afluria, in preparation for the 2014-2015 flu season, though the company said those who ordered Afluria can begin vaccinating patients as early as this month.
 
Alfuria is designed to combat types A and B of the influenza virus in patients aged 5 years or older. The most common side effect of the vaccine is soreness in the injection area.
 
bioCSL has been producing vaccinations for seasonal influenza for more than 50 years. Today, its flu vaccine is registered for use in 27 countries around the world.
 
“Our historical operational focus on early and consistent delivery has resulted in a strong customer pre-book order demand for the coming season,” said Marie Mazur, MD, President of bioCSL, in a statement. “We are committed to continuing to serve the needs of providers in the United States, and want to ensure that they are prepared to help prevent influenza in their communities.”
 
According to bioCSL, 18- to 64-year-olds were severely impacted by the 2013-2014 flu season, as approximately 60% of hospitalizations related to influenza were directly tied to this demographic. This age group also had a lower-than-average vaccination rate compared to the national average in the United States, the company noted.
 
“With each influenza season comes new challenges,” Mazur stated. “The flu is a significant public health threat. bioCSL strives to deliver vaccines to providers as early as possible to give them ample time to vaccinate against the flu.”
Related Articles
Almost all women and seniors with atrial fibrillation should be receiving blood thinners, advises a new analysis of updated clinical practice guidelines.
Pharmacists are ready to take on the job that others have overlooked.
Antibiotic prescribing rates tend to rise when retail clinics and physician offices compete for patients in affluent areas with abundant access to health care professionals.
An OTC allergy medication may be able to kill the bacteria behind Lyme disease, bringing researchers closer to developing the first targeted therapy for the debilitating infection.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$